NSCLC has been delineated as a heterogeneous disease characterized by several oncogenic driver alterations, such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK) or ROS-1 gain of function gene modifications [5, 6]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.